United States Patent 11,285,129 Tasimelteon Method Claims: Scope, Limitations, and US Patent Landscape
United States Patent 11,285,129 claims a specific clinical decision-and-dosing method for tasimelteon (20 mg once daily administered 0.5 to 1.5 hours before target bedtime) that hinges on whether the patient is taking a beta-adrenergic receptor antagonist. If not on an antagonist, the method requires dosing as specified. If on an antagonist, it requires discontinuation (instruct cease use) followed by the same tasimelteon schedule. Dependent claims narrow the antagonist list (examples) and limit the indication to Non-24-Hour Sleep-Wake Disorder.
What is US Patent 11,285,129 and what does it claim about tasimelteon dosing?
Claim 1: core improvement method
Claim 1 is structured as a two-branch “improvement” embedded inside “method of administering tasimelteon.” The operative steps are:
- Determine whether the patient “is being treated with a beta-adrenergic receptor antagonist.”
- If the patient is not being treated with a beta-adrenergic receptor antagonist:
- Administer 20 mg tasimelteon once daily about one-half hour to about one-and-one-half hours before the target bedtime.
- If the patient is being treated with a beta-adrenergic receptor antagonist:
- Instruct the patient to cease treatment with the beta-adrenergic receptor antagonist.
- Then administer 20 mg tasimelteon once daily about one-half hour to about one-and-one-half hours before the target bedtime.
Practical scope implication: infringement turns on whether a clinician (or system instructed to clinicians) performs the “determining” step and then follows the corresponding branch, including the dosing timing window and, in the antagonist branch, the discontinuation instruction for the beta-blocker.
Claim 2: beta-adrenergic receptor antagonist examples
Claim 2 limits Claim 1’s beta-adrenergic receptor antagonist to one “selected from”:
- alprenolol
- altenolol
- carvedilol
- metoprolol
- propranolol
Scope implication: Claim 2 is narrower, but Claim 1’s antagonist category is broader (not limited to these five). Claim 2 creates a separate, more easily satisfied subset.
Claim 3: indication narrowing
Claim 3 specifies:
- “patient is suffering from Non-24-Hour Sleep-Wake Disorder.”
Scope implication: Claim 3 is a narrower method for a specific therapeutic use. Claim 1 and 2 are not explicitly limited to Non-24 unless the “patient” in claim 1 is interpreted as implicitly tied to the marketed indication. As drafted, Claim 3 provides an additional clear infringement theory for N24OSWD-specific prescribing.
How broad is Claim 1: what activities do “determining” and “instructing cessation” require?
“In a method of administering tasimelteon”
This phrase ties the method to administration of tasimelteon, not merely to prescribing. For infringement risk, the steps must be performed “in a method of administering” tasimelteon to a “patient.” That generally aligns with real-world clinical practice, clinician instructions, or treatment protocols used in care.
“Determining whether” the patient is treated with a beta-adrenergic receptor antagonist
The claim does not specify how the determining occurs. It does not require lab tests, chart review method, or confirmation by prescriber. It requires a determination event, which can be satisfied by medication history review and treatment status evaluation.
The discontinuation requirement is an affirmative step
The antagonist branch requires “instructing the patient to cease treatment.” The claim does not say “reduce” or “switch,” so it is aimed at stopping the beta-adrenergic receptor antagonist. That creates a strong point of differentiation against protocols that only adjust the timing of beta-blocker dosing.
The dosing window is tight but flexible
“About one-half hour to about one-and-one-half hours before the target bedtime” is a time range with tolerances. Risk exists if tasimelteon is administered substantially within that window. If administered meaningfully outside it, the “about” language still leaves room for claim construction arguments, but outside the stated range is a non-trivial design-around lever.
When does the discontinuation branch apply: what counts as being “treated with” a beta-adrenergic receptor antagonist?
Medication status threshold
The claim requires determining “is being treated.” That implies active therapy, not past use. If the beta-blocker was discontinued before tasimelteon initiation and the patient is not on therapy at the time of determining, the “not being treated” branch is triggered.
Switching versus stopping
Because Claim 1 uses “cease treatment,” switching to another agent (even another beta-blocker) does not satisfy the requirement. A protocol that changes beta-blocker to a different class would not satisfy “cease treatment” if beta-blockade continues, but it could satisfy “cease treatment with the beta-adrenergic receptor antagonist” if the patient is no longer treated with that antagonist. The claim is about ceasing treatment with the beta-adrenergic receptor antagonist, not about ceasing “beta blockade” generally.
What is the dependent claim scope for Claim 2 beta-blockers?
Claim 2 is a closed set “selected from” five named antagonists. If the patient is treated with a beta-adrenergic receptor antagonist not listed in the five examples, Claim 2 does not require coverage. However, Claim 1 may still apply if the antagonist is still “beta-adrenergic receptor antagonist” broadly.
Named agents effect
- If the competitor’s labeling or protocol covers metoprolol, propranolol, carvedilol, or similar agents, the Claim 2 theory is direct for those five.
- If a clinician uses another beta-blocker (not listed), Claim 1’s broader language still creates risk unless the clinician can avoid the “beta-adrenergic receptor antagonist” category through substitutions or discontinuation.
What is the dependent claim scope for Claim 3 Non-24-Hour Sleep-Wake Disorder?
Claim 3 limits the method to patients suffering from Non-24-Hour Sleep-Wake Disorder. That creates a clearer pathway for enforcing the protocol in the exact approved indication context where clinicians are likely to prescribe tasimelteon.
Scope implication: A non-24-specific protocol that includes the beta-antagonist determination and discontinuation step is the highest infringement-risk scenario.
What patent estate exists around tasimelteon in the US, and how does this method patent fit?
Where method-of-use patents usually sit in the Orange Book structure
Tasimelteon has historically been protected not only by active ingredient patents but also by formulation and method-of-use patents. A method claim like 11,285,129 typically targets label-driven clinical steps, dose timing, or patient-selection criteria that can be triggered by co-medication status.
Landscape mapping by protection type (functional)
For enforcement and freedom-to-operate planning, the tasimelteon US landscape is typically analyzed by:
- Composition/formulation patents (tablet/capsule composition, excipients, release profile).
- Process/manufacturing patents (how tasimelteon is made or formulated).
- Method-of-use patents (indication-specific use, dosing regimen, patient selection).
- Combination/co-administration patents (interaction management or drug-drug timing rules).
How 11,285,129 fits: it is a method-of-use/interactions-management patent that combines (a) a co-medication status determination and (b) a dosing regimen with a discontinuation instruction and a specified dosing window.
Enforcement leverage
A beta-blocker cessation instruction can be used to argue that generic substitution or prescribing without that cessation step does not avoid the method if the claimant can prove the discontinuation instruction is part of the “method of administering” performed in practice.
How strong is the infringement case for Claim 1 given typical clinical workflows?
Most sensitive trigger: protocols that explicitly manage beta-blockers
If the reference protocol, training materials, clinical decision support, or labeling instructs clinicians to assess beta-adrenergic antagonist co-therapy and stop it before initiating tasimelteon (or before dosing within a target window), Claim 1’s steps are likely present.
Generic entry risk
For a generic applicant, risk increases if:
- clinicians follow an interaction management approach that includes stopping beta-antagonists; and
- the prescribed timing is within the “about 0.5 to 1.5 hours before bedtime” window; and
- the patient selection includes non-24 patients for Claim 3.
Risk reduces if:
- clinicians are instructed not to cease beta-antagonists, or
- dosing is outside the claimed time window, or
- tasimelteon is administered using a regimen clearly not meeting the claim steps.
What design-around paths exist that avoid the claim elements?
Avoiding the discontinuation step
If a treatment strategy uses:
- substitution to a different agent class (not a beta-adrenergic receptor antagonist), or
- maintaining beta-blocker therapy while adjusting only tasimelteon dosing timing outside 0.5 to 1.5 hours, or
- avoiding any “instruct to cease treatment with beta-adrenergic receptor antagonist,”
then Claim 1 can be avoided because the antagonist branch is not performed as claimed.
Avoiding the dosing window
Dosing tasimelteon clearly outside the “about one-half hour to about one-and-one-half hours before target bedtime” range reduces the chance that the method’s dosing limitation is met.
Avoiding the determination step
In theory, a protocol that never requires a “determining” step about beta-adrenergic antagonist status and instead uses a standardized schedule could avoid a literal performance of that limitation. In practice, clinicians usually review medication histories, so this is harder operationally.
Avoiding Non-24 indication
To avoid Claim 3, the method would have to be used for other indications or dosing contexts not meeting “suffering from Non-24-Hour Sleep-Wake Disorder.” Claim 1 and 2 do not explicitly require the indication, so avoiding Claim 3 alone may not remove all infringement risk.
What would a Paragraph IV or method-based litigation theory likely look like?
A method-of-use patent like 11,285,129 typically supports litigation theories tied to:
- whether the proposed generic label or REMS/training materials include co-medication discontinuation instructions; and
- whether “20 mg once daily” tasimelteon dosing within 0.5 to 1.5 hours pre-bed is part of the intended use; and
- whether the beta-blocker determination and discontinuation steps appear in the prescribing instructions for non-24.
A generic challenger can attempt to argue non-infringement by changing:
- the label (removing interaction management instructions),
- the dosing instructions (time window),
- or clinical guidance on beta-blocker discontinuation.
How does this patent constrain competitors: biosimilars vs generics?
Tasimelteon is a small molecule. The competitive threat is generics and any authorized generics, not biosimilars.
Generic substitution pathways that may avoid exposure
- If a generic’s FDA label omits any instruction to cease beta-adrenergic receptor antagonists and dose timing is outside the claimed range, infringement risk is reduced.
- If the generic’s label still requires interaction management with discontinuation, risk rises.
Key takeaways: scope and business impact of US 11,285,129
- Claim 1 is a conditional method: it requires determining beta-adrenergic antagonist status, then either dosing tasimelteon within 0.5 to 1.5 hours pre-bed or instructing cessation of the beta-adrenergic antagonist and then dosing on the same schedule.
- Claim 2 narrows beta-blockers to five named antagonists, but Claim 1 covers beta-adrenergic receptor antagonists broadly.
- Claim 3 locks to Non-24-Hour Sleep-Wake Disorder, creating a stronger enforcement posture in that indication.
- Most material infringement levers are (a) whether clinicians are instructed to stop beta-adrenergic receptor antagonists and (b) whether tasimelteon dosing is within the specified time window.
- Design-arounds most plausibly avoid one of the claim’s essential steps: no discontinuation instruction, no within-range dosing window, or a non-qualifying indication.
FAQs
1) What exact tasimelteon dose and timing does US 11,285,129 require?
It requires administering 20 mg tasimelteon once daily about 0.5 to 1.5 hours before target bedtime.
2) Does the patent require stopping beta-blockers or just accounting for them?
Claim 1 requires instructing the patient to cease treatment with the beta-adrenergic receptor antagonist when the determination shows the patient is being treated.
3) If the patient is on a beta-blocker not listed in Claim 2, is the method still potentially covered?
Claim 2 is limited to five named antagonists, but Claim 1 still covers beta-adrenergic receptor antagonists generally.
4) Is Non-24-Hour Sleep-Wake Disorder required for infringement?
Not for Claim 1 or 2 as written. Claim 3 adds that limitation.
5) What is the main risk for generic manufacturers launching tasimelteon under a US label?
The risk is a label or clinical practice environment that results in clinicians performing the beta-antagonist determination and discontinuation step and dosing within the 0.5 to 1.5 hour pre-bed window.
References
- United States Patent 11,285,129 (tasimelteon method of administering with beta-adrenergic receptor antagonist determination and dosing regimen).
